Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Burstein, 2010, American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, J Clin Oncol, 28, 3784, 10.1200/JCO.2009.26.3756 2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med, 353, 2747, 10.1056/NEJMoa052258 Coates, 2007, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J Clin Oncol, 25, 486, 10.1200/JCO.2006.08.8617 2009, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, N Engl J Med, 361, 766, 10.1056/NEJMoa0810818 Colleoni, 2011, Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, J Clin Oncol, 29, 1117, 10.1200/JCO.2010.31.6455 Saphner, 1996, Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, 14, 2738, 10.1200/JCO.1996.14.10.2738 Pritchard, 2011, Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important?, J Clin Oncol, 29, 1651, 10.1200/JCO.2010.34.2766 Giobbie-Hurder, 2009, Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer, Clin Trials, 6, 272, 10.1177/1740774509105380 Hudis, 2007, Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system, J Clin Oncol, 25, 2127, 10.1200/JCO.2006.10.3523 Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J Clin Oncol, 28, 509, 10.1200/JCO.2009.23.1274 Regan, 2011, Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer, Breast Cancer Res, 13, 209, 10.1186/bcr2837 Baum, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 Finkelstein, 2011, Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 Trial by using the inverse probability of censoring weighted method, J Clin Oncol, 29, 1093, 10.1200/JCO.2010.33.9374 Mauriac, 2007, Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Ann Oncol, 18, 859, 10.1093/annonc/mdm001 Viale, 2011, Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial, Ann Oncol, 22, 2216, 10.1093/annonc/mdq738 Goldhirsch, 2007, Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007, Ann Oncol, 18, 1133, 10.1093/annonc/mdm271 Lazar, 2010, Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot, J Clin Oncol, 28, 4539, 10.1200/JCO.2009.27.9182 Amir, 2011, Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis, J Natl Cancer Inst, 103, 1, 10.1093/jnci/djr242 Goss, 2003, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 349, 1793, 10.1056/NEJMoa032312 Mamounas, 2008, Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial, J Clin Oncol, 26, 1965, 10.1200/JCO.2007.14.0228 Jordan, 2008, The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death?, J Clin Oncol, 26, 3073, 10.1200/JCO.2008.17.5190 Sabnis, 2008, Stopping treatment can reverse acquired resistance to letrozole, Cancer Res, 68, 4518, 10.1158/0008-5472.CAN-07-5999